Tirbanibulin Mesylate is primarily used in dermatology for the treatment of actinic keratosis, a precancerous skin condition caused by prolonged sun exposure. It works by inhibiting cell proliferation and promoting apoptosis in affected skin cells, effectively reducing the lesions. The compound is applied topically as an ointment, once daily to the affected area for 5 consecutive days, making it a convenient and targeted treatment option. Its efficacy and minimal systemic absorption make it suitable for patients seeking a non-invasive approach to managing this condition. It is generally well-tolerated, with possible mild side effects such as redness, itching, or irritation at the application site. Regular application as prescribed helps in clearing the lesions and preventing potential progression to skin cancer.